AMES, Iowa, Aug. 3 /PRNewswire-FirstCall/ -- BioForce Nanosciences , manufacturer of the NanoArrayer(TM) System for enabling new nanotechnology applications, has announced the placement of a NanoArrayer in Paris at the Universite Pierre & Marie Curie (UPMC) for technology evaluation by CNRS (Centre National de la Recherche Scientifique), the French National Center for Scientific Research.
The NanoArrayer was installed in May in the laboratory of Dr. Fatiha Nothias who noted, “Our plan is to use the unique printing capabilities of the NanoArrayer to pattern proteins associated with cell morphology establishment and migration.” Dr Nothias said, “Our end goal is to determine the consequences of the interactions of neurons and glial cells with these patterned proteins.” Other French research groups in the same institute have expressed interest in utilizing the NanoArrayer to study how cells sense their environment during the organization of the embryonic tissue.
Michael Lynch, Product Manager for the NanoArrayer, assisted with the installation and training process. He noted that, “The NanoArrayer enables protein patterning in the significantly small dimensions required to study single cell growth and development important in Neuroscience, Cancer Biology, Stem Cell Research, Genetic Disease and more.” Lynch added, “This installation also provided an opportunity to introduce NanoAndMore, our European distributor for the NanoArrayer product line, to these new and exciting markets.”
“This technology agreement partnership with UPMC and CNRS provides BioForce with valuable new market applications of the NanoArrayer,” noted Kerry Frey, BioForce COO. “Our goal is continued growth into emerging new bionanotechnology markets in Europe and this placement, our second overseas this year, continues our progress.”
About BioForce Nanosciences, Inc.
BioForce Nanosciences is a nanotechnology tools and applications Company, providing innovative and practical products that support the growth of the nanotechnology industry. The Company has spent more than a decade of invention, research and development on patented and patent-pending nanotechnology products. The core technology is the NanoArrayer(TM) Benchtop Molecular Printer, a portal to new opportunities in nanotechnology. The NanoArrayer opens the door to new and important applications in the biomedical and life sciences markets that lead to improved quality of life. BioForce continues to target inventions that further expand the reach of its proprietary technology and expand its robust patent, trademark and IP portfolio.
BioForce Nanosciences, Inc., the Practical Nanotechnology(TM) company brings inventions to the marketplace that complement existing innovations, licensing and acquisitions. BioForce is a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. . For more information, visit http://www.bioforcenano.com or contact BioForce at info@bioforcenano.com or 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the company’s most recent filings with the Securities and Exchange Commission. The company’s actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.
BioForce Nanosciences, Inc.
CONTACT: Eric Henderson, Ph.D. of BioForce Nanosciences, Inc.,+1-515-233-8333 Ext. 101, ehenderson@bioforcenano.co; or Michelle Manoff ofRubenstein PR, +1-212-843-8051, mmanoff@rubensteinpr.com, for BioForceNanosciences
Web site: http://www.bioforcenano.com/
